Product Images Erleada

ERLEADA is a medication that appears to be effective in treating conditions that Placebo can't treat. The efficacy of ERLEADA can be observed over 2-3 months where it can help patients recover. The medication appears to be in trial phases as the data presented pertains to randomized groups of individuals. The medication has some risk of producing unwanted side effects.*

This is a graph that compares the effectiveness of the drug ERLEADA versus a placebo. The graph shows the percentage of subjects, out of a total of 527 for the placebo and 525 for ERLEADA, who did not experience a certain “event” (information about which is not available based on this text) over a period of 36 months. The results showed that a higher percentage of subjects taking ERLEADA did not experience the event compared to the placebo group. The number of subjects who were at risk of experiencing the event decreased over time for both groups.*

ERLEADA is a medication that appears to drastically increase the survival rate of patients after diagnosis. At 16 months from randomization, more than twice as many patients on ERLEADA were still alive when compared to those who were given a placebo. The results of the trial show an increasing gap in survival rates between the two groups over time, which may make it a promising option for individuals who have received such a diagnosis.*

This appears to be a graph showing the death-free survival probabilities over time for two different treatments: Placebo and ERLEADA. The x-axis measures the months from randomization and the y-axis measures the death-free survival probability in percent from 0% to 100%. However, there is not enough data being provided to fully understand the context of the graph.*

This is a description of prescription tablets named Erleada, with NDC number 59676-600-12, which contains 60mg of Apalutamide per tablet. The package contains 120 tablets and the text contains a warning that it should be used only under medical supervision.*